Hemophilia Management

Introduction

Expert Interview

Stay Connected

Join the conversation

Hemophilia Quick Facts

Although President Trump has pledged to dismantle the current healthcare system and replace the Affordable Care Act, it is unlikely that changes will be immediate. Furthermore, President Trump has indicated that he would retain many popular provisions, including those surrounding coverage for pre-existing conditions, such as hemophilia.

  • The Affordable Care Act provides insurance to an estimated 20 million Americans, so “repeal and replace” would likely take a significant amount of time to be implemented.
  • Experts maintain it is unlikely that the President and Congress will do anything that affects Marketplace beneficiaries in 2017.
    • With open enrollment currently underway, the Obama administration had estimated >11.4 million people will be insured through health insurance exchanges in 2017.
  • For those with pre-existing conditions specifically, the following potential changes have been surmised:
    • Maintaining the moratorium on charging more or denying coverage for those with pre-existing conditions, assuming those individuals have consistently paid their premiums
    • Working with states to establish high-risk pools to cover those with chronic medical conditions

Luhby T. Obamacare under President Trump: What happens next?

Questionnaire

Q1: What best describes your primary role?

Q2: Approximately how many patients with hemophilia are being managed in your plan or practice setting?

Q3: How concerned are you regarding potential changes to the Affordable Care Act?

Q4: Which of the below topics do you most need further information on?

Advisory Board

Jennifer Maahs, RN, PNP, MSN
Nurse Practitioner
Indiana Hemophilia and Thrombosis Center

Vanita K. Pindolia, PharmD, BCPS
Vice President, Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System/Health Alliance Plan of Michigan

Steven W. Pipe, MD
Director, Division of Pediatric Hematology and Oncology
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
University of Michigan

Marion Koerper, MD Professor Emerita on Recall
Department of Pediatric Hematology
School of Medicine University of California, San Francisco
(UCSF) School of Medicine
Medical Advisor
National Hemophilia Foundation

Diane J. Nugent, MD Chair, Hematology
Medical Director, Hematology and Blood and Donor Services
Division Chief, Hematology
Children’s Hospital of Orange County

Celynda G. Tadlock, PharmD, MBA
Vice President Pharmacy Business Development, Aetna
President, Coventry Prescription Management Serivces, Inc.